Skip To Main Content
Shuying Dong on Muck Rack

Shuying Dong

As seen in: Frontiers, Dove Medical Press
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Shuying

Contact Shuying, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Application of case-based study promoting the outcome-based education concept in clinical pharmacotherapeutic teaching: a pre-post study with implications for medical educator development

|
By Meiling Yu, Shuying Dong, Yingying Huang, Lingti Kong, Daohua Guo, Xuhui Tong
| Frontiers
Abstract Background: Although outcome-based education (OBE) and case-based study (CBS) are commonly used in health professions education, there are ongoing issues with the standardization of faculty evaluation rubrics and the integration of teaching with core competencies. This study aimed to rectify these issues in clinical pharmacotherapeutic education. Methods: A total of 78 undergraduate clinical pharmacy students participated in this pre–post study.
Open in Who Shared Issue with article?

Dupilumab for Atopic Dermatitis with Twenty-Nail Dystrophy: A Case Rep

|
By Ji Li, Duo Zhang, Lili Zhu, Shuying Dong
| Dove Medical Press
Introduction Cutaneous findings in atopic dermatitis (AD) are well recognized, while nail changes are often overlooked. Approximately 11% of patients with AD exhibit nail changes, which may manifest as distinctive alterations such as pitting, longitudinal striations, and increased fragility.1 However, atopic dermatitis presenting with twenty-nail dystrophy has not been reported. We report a case of AD characterized by TND, which was successfully managed with dupilumab.
Open in Who Shared Issue with article?
See all 2 articles